Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia

INTRODUCTION: Solanezumab is a monoclonal antibody that preferentially binds soluble amyloid beta and promotes its clearance from the brain. The aim of this post hoc analysis was to assess the effect of low‐dose solanezumab (400 mg) on global brain volume measures in patients with mild or moderate A...

Descripción completa

Detalles Bibliográficos
Autores principales: Svaldi, Diana Otero, Higgins, Ixavier A., Holdridge, Karen C., Yaari, Roy, Case, Michael, Bracoud, Luc, Scott, David, Shcherbinin, Sergey, Sims, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237342/
https://www.ncbi.nlm.nih.gov/pubmed/35783453
http://dx.doi.org/10.1002/trc2.12313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237342/
https://www.ncbi.nlm.nih.gov/pubmed/35783453
http://dx.doi.org/10.1002/trc2.12313

Ejemplares similares